Latest Breaking News On - Hyung heon kim - Page 1 : comparemela.com

NeuroBo Pharmaceuticals DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that pre-clinical data suggests that DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist,.

United kingdomMonika lewinskaSujin leeHenrikb hansenMarshallh woodworthAhyoung kimMichael feighHoon jungMi kyung kimYuna chaeMichael millerNeurobo pharmaceuticalsDonga st research centerMembers of the donga st research centerContract research organizationExchange commission

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAlexander preziosoMichael millerMarshallh woodworthDonga st coFund the company into fourth quarterNeurobo pharmaceuticals incNeurobo pharmaceuticalsAmerican diabetes associationDevelopment rd expensesSafety review committeeNeurobo pharmaceuticals inc nasdaqDosed first patientSingle ascending dose partWith top line data readout expected

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,.

United statesUnited kingdomMichael feighAhyoung kimMichael millerYuna chaeSu jin leeHoon jungHenrikb hansenMonika lewinskaSujin leeShun jungMi kyung kimMarshallh woodworthNeurobo pharmaceuticalsAmerican diabetes association

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomMarshallh woodworthMichael millerNeurobo pharmaceuticals incRx communications groupPrnewswire neurobo pharmaceuticals incDonga st coNeurobo pharmaceuticalsFull data readout expectedSecond halfG protein coupled receptorHyung heon kimChief executive officerMetabolic dysfunction associated steatohepatitisPrivate securities litigation reform act

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose.

United statesUnited kingdomAlexander preziosoMarshall woodworthJamesp tursiDevelopment rd expensesNeurobo pharmaceuticals inc nasdaqFund the company into fourth quarterDonga st coGovernance committeeDrug administrationNeurobo pharmaceuticalsNeurobo pharmaceuticals incSafety review committeeReceived first site institutional review boardProceed with